Novo Nordisk Inc. convinced a jury to reject claims that the pharmaceutical giant defrauded Washington state’s Medicaid by improperly billing the health-care program for its hemophilia drug NovoSeven.
The government and whistleblower Jamie Siegel didn’t demonstrate that the company violated the False Claims Act, according to a Nov. 7 judgment on jury verdict that followed a 15-day trial.
Siegel alleged in 2015 that Novo Nordisk promoted NovoSeven for off-label uses—such as prophylaxis and doses exceeding the FDA-approved amount—and by providing kickbacks to physicians to prescribe the drug. The suit filed in the US District Court for the Western District of ...
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Log in to keep reading or access research tools and resources.
TELEGRAPH MEDIA GROUP HOLDINGS Ltd Thank you for your interest. Unauthorised access is prohibited. To access this content, you must have prior permission and a valid contract. Please contact our te...